<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Kinases have been studied as potential <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> targets because they play important roles in the cellular signaling of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>A number of small molecules targeting kinases are prescribed in clinics and many kinase inhibitors are being evaluated in the clinical phase </plain></SENT>
<SENT sid="2" pm="."><plain>Previously, we discovered a series of <z:chebi fb="0" ids="38207">aminopyridines</z:chebi> substituted with <z:chebi fb="0" ids="46700">benzoxazole</z:chebi> as orally active c-Met kinase inhibitors </plain></SENT>
<SENT sid="3" pm="."><plain>One of the compounds, KRC-108, has been evaluated as an anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> agent in vitro and in vivo </plain></SENT>
<SENT sid="4" pm="."><plain>A kinase panel assay exhibited that KRC-108 is a potent inhibitor of Ron, Flt3 and TrkA as well as c-Met </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, KRC-108 inhibited oncogenic c-Met M1250T and Y1230D more strongly than <z:mp ids='MP_0002169'>wild type</z:mp> c-Met </plain></SENT>
<SENT sid="6" pm="."><plain>The anti-proliferative activity of KRC-108 was measured by performing a cytotoxicity assay on a panel of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines </plain></SENT>
<SENT sid="7" pm="."><plain>The GI(50) values (i.e., 50% inhibition of cell growth) for KRC-108 ranged from 0.01 to 4.22 μM for these <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines </plain></SENT>
<SENT sid="8" pm="."><plain>KRC-108 was also effective for the inhibition of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in human HT29 <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and NCI-H441 <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> in athymic BALB/c nu/nu mice </plain></SENT>
<SENT sid="9" pm="."><plain>This molecule should serve as a useful lead for inhibitors targeting kinases and may lead to new therapeutics for the treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>